Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Pulmonary Patient Equipment Supplied In Usa
5 equipment items found
Manufactured by:Medical Positioning, Inc. (MPI) based inKansas City, KANSAS (USA)
Patients easily achieve steady-state exercise with this cycle ergometer, allowing for accurate intracardiac hemodynamic assessment during nuclear studies and right heart catheterization. We designed the Cath Ergometer® for use with cath or nuclear tables. Technologists can custom fit and adjust this cycle ergometer from patient to patient for right heart catheterizations. The cycle ergometer ...
Manufactured by:United Biologics, Inc. based inIrvine, CALIFORNIA (USA)
Designed for Emerging Pulmonary Segment: Developed from DICOM Data, ensuring clinical accuracy when navigating the Right Atrium, Right Ventricle & Pulmonary Arteries. Lifelike Pulmonary Embolism (PE) & Deep Vein Thrombosis (DVT) ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
We are developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections, a main contributor to morbidity and mortality in this disease. Phase 1b/2a clinical study in CF patients is composed of two parts. Results from Part 1 aimed to evaluate the safety, pharmacokinetics, and microbiologic/clinical activity are expected in Q3 of 2022. ...
Manufactured by:Microbion Corporation based inBozeman, MONTANA (USA)
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. Chronic pulmonary infections in CF patients, a significant portion which involves Pseudomonas aeruginosa, are ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective ...